Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to
COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the …

Introduction: Corona virus is a group of viruses that cause diseases in mammals and birds.
In humans, these families of viruses can cause respiratory infections from a mild form to fatal …

Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine
storm. Therefore, treatment with immunomodulating agents should be initiated as soon as …

Background The release of pro-inflammatory cytokines, resulting in cytokine storm
syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This …

Tocilizumab decreases inflammatory response in the cytokine storm which is one of the
mechanisms behind the development of ARDS in COVID-19 patients. The objective of our …

Tocilizumab is one of the newest therapeutic options for the acute respiratory distress
syndrome (ARDS) caused by the recently discovered severe acute respiratory syndrome …

Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the
inflammatory response and control the symptoms of severe coronavirus disease 2019 …

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2),
emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease …

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a …

Background: Coronavirus disease 19 (COVID-19) can have a severe presentation
characterized by a dysregulated immune response requiring admission to the intensive care …